SLE-BRAVE I and II.

Abstract

Rheumatologists and dermatologists are comfortable with baricitinib, an oral selective inhibitor of Janus kinase 1 and Janus kinase 2, already approved and widely in use for the management of rheumatoid arthritis, atopic dermatitis, and alopecia areata. The phase 2 studies in systemic lupus erythematosus (SLE) were promising, 1 Wallace DJ Furie RA Tanaka Y et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018; 392: 222-231 Summary Full Text Full Text PDF PubMed Scopus (292) Google Scholar in particular for articular and mucocutaneous manifestations. The mechanisms of action seemed plausible and safety signals were acceptable. The rheumatology community were excited to see how this drug performed in SLE, an area of great clinical need. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)The primary endpoint in this study was met for the 4 mg baricitinib group. However, key secondary endpoints were not. No new safety signals were observed. Full-Text PDF Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)Although phase 2 data suggested baricitinib as a potential treatment for patients with SLE, which was supported in SLE-BRAVE-I, this result was not replicated in SLE-BRAVE-II. No new safety signals were observed. Full-Text PDF